Stock AnalizSmith & Nephew PLC SNN
Industrial Specialties · data as of November 13, 2026
Smith & Nephew PLC (SNN) is a healthcare company listed in the US with a market value of about $13.1B. In the twelve months to June 30, 2026 it had revenue of $6.3B and net income of $635M, a net margin of 10.1%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is shareholder returns (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 21.3, a price to free cash flow of 15.3, 5-year revenue growth of 6% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 17% below the current price.
Score: 2.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.3B | $6.2B | $5.8B | $5.5B | $5.2B | $5.2B | $4.6B | $5.1B | $4.9B | $4.8B | $4.7B |
| Net income | $635M | $625M | $412M | $263M | $223M | $524M | $448M | $600M | $663M | $767M | $784M |
| Free cash flow | $855M | $852M | $606M | $181M | $110M | $469M | $492M | $760M | $584M | $714M | $457M |
| EPS (diluted) | $1.45 | $1.49 | $0.98 | $0.63 | $0.53 | $1.25 | $1.07 | $1.43 | $1.58 | $1.83 | $1.87 |
| Net margin | 10.1% | 10.1% | 7.1% | 4.7% | 4.3% | 10.1% | 9.8% | 11.7% | 13.5% | 16.1% | 16.8% |
| ROIC | — | 7.6% | 6.5% | 4.8% | 5.4% | 6.1% | 2.7% | 9.4% | 11.6% | 13.4% | 10.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $33.19, 6% above the current price; targets range from $30.90 to $38.00; the consensus rating is “Hold”; expected EPS is $2.15 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Smith & Nephew’s P/E ratio?
About 21.3, based on the last twelve months of diluted earnings per share (forward P/E about 13.3).
Is Smith & Nephew stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 17% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Smith & Nephew pay a dividend?
Yes. The dividend yield is about 2.54%, and it has paid dividends for 10 years in our data.
Is Smith & Nephew a good stock to buy?
We do not give buy or sell advice. Smith & Nephew scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.